Modality
ADC
MOA
MALT1i
Target
GLP-1R
Pathway
Epigenetic
IPF
Development Pipeline
Preclinical
~Jan 2019
→ ~Apr 2020
Phase 1
~Jul 2020
→ ~Oct 2021
Phase 2
Jan 2022
→ Jul 2028
Phase 2Current
NCT04736112
1,768 pts·IPF
2022-01→2028-07·Completed
NCT06438415
928 pts·IPF
2023-05→2025-05·Not yet recruiting
2,696 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-05-2810mo agoPh3 Readout· IPF
2028-07-022.3y awayPh3 Readout· IPF
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P2/3
Complet…
P2/3
Not yet…
Catalysts
Ph3 Readout
2025-05-28 · 10mo ago
IPF
Ph3 Readout
2028-07-02 · 2.3y away
IPF
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04736112 | Phase 2/3 | IPF | Completed | 1768 | HbA1c |
| NCT06438415 | Phase 2/3 | IPF | Not yet recr... | 928 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Mavuglumide | Bayer | Approved | GLP-1R |